Journal Scans
Everolimus Plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated With Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-Controlled, Phase 3 Study
Everolimus + Octreotide LAR Beneficial in Advanced Neuroendocrine Tumors
ME Pavel, JD Hainsworth, E Baudin, JC Yao, et al
20111025
2011 Nov 25
Lancet
Everolimus Plus Octreotide Long-Acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated With Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-Controlled, Phase 3 Study
Lancet. 2011 Nov 25;[Epub Ahead of Print], ME Pavel, JD Hainsworth, E Baudin, JC Yao, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We aimed to assess the combination of everolimus plus octreotide long-acting repeatable (LAR) in patients with low-grade or intermediate-grade neuroendocrine tumours (carcinoid).Methods: We did a randomised, double-blind, placebo-controlled, phase 3 study comparing 10 mg per day oral everolimus with placebo, both in conjunction...
